{"id":115774,"title":"Nanograb: Deliver mRNA to any cell with AI","tagline":"Announcing NGX1, a platform for designing multi-peptide targeted lipid nanoparticles (tLNPs)","body":"**TLDR** Nanograb is announcing NGX1, a universal navigation system for mRNA drugs to deliver cures for any disease. Moderna proved that mRNA will transform skin cancer care, we expand this to all diseases.\n\n\u003chttps://youtu.be/ORfErxU5OKk\u003e\n\nDelivery is one of the most important problems stopping life-changing mRNA drugs reaching millions. There are over 3,000 different cell types in the body, but mRNA drug developers can only hit 1% of them. The problem is so pressing that multiple public biopharma partners are paying for early access to NGX1.\n\n![uploaded image](/media/?type=post\u0026id=115774\u0026key=user_uploads/983241/4aac129e-0ad7-45af-9e54-ea4997a5c9d4)\n\n**Works the first time, every time.** There are more peptide sequences than atoms in the universe. Most approaches to solve delivery rely on screening thousands of formulations. NGX1’s biophysics-informed models achieved \u003e25% hit rates on the first try across different targets in mice (4x improvement in cancer cells, 15x for immune cells).\n\n**We hit any cell, any state.** All cells have receptors. Their combination makes up a unique fingerprint. Most people try and target individual receptors whereas we can target the fingerprint, enabled by multivalent physics. We’re creating new drugs that have never existed before. \n\n**NGX1 solves major scale-up issues upfront.** Scaling up targeted mRNA drugs to millions of people is hard because of complex biomanufacturing requirements. Nanograb circumvents these requirements by utilising short peptides instead of antibodies or other biologics.\n\n**15 years of physics research powers NGX1.** Our team includes the foundational researchers of the multivalent biophysics models powering our platform. Our founding team are scientists from Imperial, Oxford and Cambridge.\n\n![uploaded image](/media/?type=post\u0026id=115774\u0026key=user_uploads/983241/1afa2be9-6b73-405a-9931-042318f53d19)\n\nModerna has already shown that mRNA drugs are the future. Eli Lilly showed that mRNA’s potential to be a one-time solution for high cholesterol could help the entire global population. NGX1 is the first step to realising a future where millions of people can access mRNA therapies.\n\nLearn more at [nanograb.com](http://nanograb.com) or reach out via [platform@nanograb.com](mailto:platform@nanograb.com).","slug":"U7K-nanograb-deliver-mrna-to-any-cell-with-ai","created_at":"2026-09-17T15:45:22.879Z","updated_at":"2026-09-19T09:00:28.007Z","total_vote_count":7,"url":"https://www.ycombinator.com/launches/U7K-nanograb-deliver-mrna-to-any-cell-with-ai","share_image_url":"https://www.ycombinator.com/media/?type=post\u0026id=115774\u0026key=user_uploads/983241/4aac129e-0ad7-45af-9e54-ea4997a5c9d4","company":{"id":29051,"name":"Nanograb","slug":"nanograb","url":"https://nanograb.com","logo":"https://bookface-images.s3.amazonaws.com/small_logos/9ae1f1866a70286591b56aa5fd2f81bdf18af255.png","batch":"Summer 2023","industry":"Healthcare","tags":["AI-powered Drug Discovery","Nanomedicine","Biotech","Drug Delivery","Therapeutics"],"search_path":"https://bookface.ycombinator.com/company/29051"}}